Nurix Therapeutics
- Founded: 2009
- Location: San Francisco, CA
- Employee range: 200 - 500
- Clinical stage: Clin1b
- Therapy area: B-cell malignancies
- Drug types: ONC, RHU, IMM
- Lead product: NX-2127
- Product link: https://www.nurixtx.com/pipeline/
- Funding: $40M stock Jul 2022; $55M stock Jul 2022; $160M stock Mar 2021; $209M IPO Jul 2020; $120M Mar 2020
- Investors: Foresite Capital, Bain Capital Life Sciences, Boxer Capital (Tavistock Group), EcoR1 Capital, Redmile Group, Wellington Management Company, The Column Group, Third Rock Ventures
nurixtx.com linkedin.com job board
Short description:
Small Molecules, Protein Degradation
Drug notes:
NX-5948 Clin1a B-cell malignancies; NX-1607 Clin1a immuno-oncology; NX-0479 Clin0 rheumatoid arthritis, inflammatory diseases; 3 undisclosed programs RD undisclosed
Long description:
Nurix Therapeutics is discovering and developing therapies that modulate protein levels to treat cancer. Proteins are the workhorse of a cell and can become overexpressed, underexpressed or over-activated in diseases like cancer. Nurix is addressing these diseases through ‘Targeted Protein Modulation’ that enables tuning of specific protein levels. This can be used to destroy disease-causing proteins or to inhibit protein degraders and raise the level of beneficial proteins. Discovery involves use of Nurix’s DELigase platform to identify small molecules that bind their collection of E3 ligases. Nurix has identified a CBL-B ligase inhibitor that they are using to create superior adoptive cell therapies which are entering clinical trials.
© 2023 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com